Overview

A Study of Distal Jejunal-release Dextrose in Obese Participants

Status:
Not yet recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.
Phase:
Phase 2
Details
Lead Sponsor:
Aphaia Pharma US LLC